<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424541</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A1104</org_study_id>
    <nct_id>NCT00424541</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>A Multiple Center, Randomized, Double Blind, Parallel Group, Multiple Oral Doses Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profiles of 150 mg and 300 mg of SPP100 in Japanese Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the&#xD;
      relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood&#xD;
      pressure lowering effects of oral doses of SPP100 in Japanese patients with mild to moderate&#xD;
      essential hypertension. Safety will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic profile of aliskiren administration after meal Day 1, Day 14, and Day 28</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of aliskiren on the RAS profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship among steady state pharmacokinetics, change in RAS biomarkers and blood pressure lowering effect of aliskiren</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPP100 (aliskiren)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese patients with mild to moderate essential hypertension aged 20 to 80 years&#xD;
&#xD;
          -  Blood pressure: Mean (based on 3 recordings at 1-2 minute intervals) sitting diastolic&#xD;
             blood pressure values on 14 days or 3 days before the treatment should meet the&#xD;
             following criteria:&#xD;
&#xD;
               -  14 days before treatment: ≥ 90 mmHg and &lt; 110 mmHg&#xD;
&#xD;
               -  3 days before treatment: ≥ 95 mmHg and &lt; 110 mmHg&#xD;
&#xD;
               -  The difference in mean sitting diastolic blood pressure between 14 days and 3&#xD;
                  days before the treatment is within 10 mmHg&#xD;
&#xD;
          -  Body weight no less than 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with mean (based on 3 recordings at 1-2 minute intervals) systolic blood&#xD;
             pressure ≥ 180 mmHg and/or mean diastolic blood pressure ≥ 110 mmHg at Day -28, Day&#xD;
             -14 and Day -3.&#xD;
&#xD;
          -  Patients with or suspected of having secondary hypertension&#xD;
&#xD;
          -  Patients suspected of having malignant hypertension&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2500</url>
    <description>Results for CSPP100A1104 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2007</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <keyword>Pharmacokinetics, pharmacodynamics, safety, RAS profile, SPP100, aliskiren, Japanese, essential hypertension</keyword>
  <keyword>Mild to moderate essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

